Amneal Pharmaceuticals (AMRX) News Today $8.07 +0.32 (+4.13%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Price Up 4.5% - Here's What HappenedAmneal Pharmaceuticals (NASDAQ:AMRX) Trading 4.5% Higher - What's Next?December 17 at 4:24 PM | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) have received an average rating of "Moderate Buy" from the five research firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and four have given a buDecember 15 at 6:15 AM | marketbeat.comBNP Paribas Financial Markets Trims Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)BNP Paribas Financial Markets lowered its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 88.1% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 54,398 shares of the company's stock after sellingDecember 15 at 3:22 AM | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Sold by Jacobs Levy Equity Management Inc.Jacobs Levy Equity Management Inc. lowered its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 66.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 97December 10, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Raises Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Charles Schwab Investment Management Inc. lifted its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 16.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,404,883 shDecember 9, 2024 | marketbeat.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Pacira Pharmaceuticals (PCRX), Amneal Pharmaceuticals (AMRX) and NextCure (NXTC)December 6, 2024 | markets.businessinsider.comWalleye Capital LLC Purchases Shares of 131,667 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Walleye Capital LLC acquired a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 131,667 shares of the company's stock, valued at approximately $1,095,000.December 6, 2024 | marketbeat.comPolar Asset Management Partners Inc. Purchases 216,400 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Polar Asset Management Partners Inc. lifted its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 122.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 393,000 shareDecember 5, 2024 | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Bought by Quantbot Technologies LPQuantbot Technologies LP lifted its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 274.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 111,181 shares of the company'sDecember 2, 2024 | marketbeat.comAmneal resubmits DHE autoinjector NDA, gets FDA approval for exenatideNovember 22, 2024 | markets.businessinsider.comAmneal Resubmits New Drug Application for Migraine Treatment, Diabetes Drug Is ApprovedNovember 21, 2024 | marketwatch.comAmneal gets FDA approval for generic Byetta, resubmits DHE NDANovember 21, 2024 | msn.comAmneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 AgonistNovember 21, 2024 | businesswire.comGSA Capital Partners LLP Decreases Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)GSA Capital Partners LLP reduced its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 64.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 54,350 shares of the company's stockNovember 21, 2024 | marketbeat.comJason B. Daly Sells 43,657 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) StockNovember 20, 2024 | insidertrades.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Average Recommendation of "Moderate Buy" by AnalystsAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) has earned an average rating of "Moderate Buy" from the five research firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating tNovember 20, 2024 | marketbeat.comPhocas Financial Corp. Reduces Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Phocas Financial Corp. decreased its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 5.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,015,190 shares of the company'November 19, 2024 | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Down 16.3% in OctoberAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) was the recipient of a significant decrease in short interest in October. As of October 31st, there was short interest totalling 3,500,000 shares, a decrease of 16.3% from the October 15th total of 4,180,000 shares. Approximately 2.9% of the company's stock are short sold. Based on an average trading volume of 1,190,000 shares, the days-to-cover ratio is presently 2.9 days.November 15, 2024 | marketbeat.comAmneal Pharmaceuticals price target raised to $11 from $9 at Piper SandlerNovember 11, 2024 | markets.businessinsider.comAmneal Pharmaceuticals (NASDAQ:AMRX) Hits New 12-Month High Following Analyst UpgradeAmneal Pharmaceuticals (NASDAQ:AMRX) Reaches New 1-Year High on Analyst UpgradeNovember 11, 2024 | marketbeat.comPiper Sandler Issues Positive Forecast for Amneal Pharmaceuticals (NASDAQ:AMRX) Stock PricePiper Sandler lifted their price target on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an "overweight" rating in a research note on Monday.November 11, 2024 | marketbeat.comAmneal Pharmaceuticals, Inc. (NYSE:AMRX) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | msn.comAmneal Pharmaceuticals Reports Q3 2024 Financial ResultsNovember 9, 2024 | markets.businessinsider.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Sold by Nisa Investment Advisors LLCNisa Investment Advisors LLC lowered its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 96.9% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 7,069 shares of the company's stock after selling 221,848 shares durNovember 9, 2024 | marketbeat.comAmneal Pharmaceuticals, Inc. (AMRX) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | seekingalpha.comAmneal Pharmaceuticals backs FY24 adjusted EPS view 57c-63c, consensus 60cNovember 8, 2024 | markets.businessinsider.comGeneric Drug-Focused Amneal Beats Q3 Expectations, Reaffirms Annual ForecastsNovember 8, 2024 | finance.yahoo.comAmneal Pharmaceuticals Swings to 3Q Loss While Sales ClimbNovember 8, 2024 | marketwatch.comAmneal Pharmaceuticals Profit Slips, Yet Beats Estimates; Backs Annual Outlook In Line With ViewNovember 8, 2024 | markets.businessinsider.comAmneal Pharmaceuticals (NASDAQ:AMRX) Releases FY 2024 Earnings GuidanceAmneal Pharmaceuticals (NASDAQ:AMRX) updated its FY 2024 earnings guidance. The company provided EPS guidance of 0.570-0.630 for the period, compared to the consensus estimate of 0.600. The company also issued revenue guidance of $2.7 billionillion-$2.8 billionillion, compared to the consensus estimate of $2.8 billionillion.November 8, 2024 | marketbeat.comAmneal Reports Third Quarter 2024 Financial ResultsNovember 8, 2024 | businesswire.comAmneal Pharmaceuticals (AMRX) Receives a Buy from BarclaysNovember 8, 2024 | markets.businessinsider.comEarnings Outlook For Amneal PharmaceuticalsNovember 7, 2024 | benzinga.comAmneal Pharmaceuticals Q3 2024 Earnings PreviewNovember 7, 2024 | msn.comWhat's Next: Amneal Pharmaceuticals's Earnings PreviewNovember 7, 2024 | benzinga.comEarnings To Watch: Amneal Pharmaceuticals Inc (AMRX) Reports Q3 2024 ResultNovember 7, 2024 | finance.yahoo.comZacks.com featured highlights include Amneal Pharmaceuticals, Cronos Group, Carriage Services, Business First Bancshares and AmphenolNovember 6, 2024 | au.finance.yahoo.comAmneal Pharmaceuticals (AMRX) Scheduled to Post Quarterly Earnings on FridayAmneal Pharmaceuticals (NASDAQ:AMRX) will be releasing earnings before the market opens on Friday, November 8, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=633918)November 1, 2024 | marketbeat.comAmneal Pharmaceuticals (NASDAQ:AMRX) grows 3.0% this week, taking five-year gains to 211%October 31, 2024 | finance.yahoo.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Sees Significant Decline in Short InterestAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) was the recipient of a significant decrease in short interest during the month of October. As of October 15th, there was short interest totalling 4,180,000 shares, a decrease of 7.7% from the September 30th total of 4,530,000 shares. Based on an average daily volume of 1,230,000 shares, the short-interest ratio is presently 3.4 days. Approximately 3.5% of the company's shares are short sold.October 30, 2024 | marketbeat.comAssenagon Asset Management S.A. Raises Stock Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Assenagon Asset Management S.A. grew its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 114.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,204,994 shares of the company's stock afOctober 28, 2024 | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the five research firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation anOctober 26, 2024 | marketbeat.comAmneal Pharmaceuticals receives FDA approval of Pyridostigmine Bromide NDAOctober 22, 2024 | markets.businessinsider.comAmneal Pharmaceuticals Gets FDA Approval for Pyridostigmine BromideOctober 21, 2024 | marketwatch.comAmneal Pharma: FDA Approves NDA For Pyridostigmine Bromide Extended-Release TabletsOctober 21, 2024 | markets.businessinsider.comAmneal Pharmaceuticals (NASDAQ:AMRX) Sets New 12-Month High - What's Next?Amneal Pharmaceuticals (NASDAQ:AMRX) Hits New 12-Month High - Here's WhyOctober 16, 2024 | marketbeat.comSG Americas Securities LLC Buys Shares of 63,844 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)SG Americas Securities LLC purchased a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 63,844 shares of the company's stock, valued at approximatelyOctober 16, 2024 | marketbeat.comCoya Therapeutics Has Several Near-Term Share Price Appreciation CatalystsOctober 13, 2024 | seekingalpha.comAmneal Pharmaceuticals Inc (AMRX) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...October 9, 2024 | finance.yahoo.comSei Investments Co. Raises Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Sei Investments Co. raised its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 257.9% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 127,100 shares of the company's stock after acquiring an additional 91,584 shares during theOctober 9, 2024 | marketbeat.com Get Amneal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address DeFi Coin on Verge of Breakout! (Ad)The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Claim your FREE book now before it's too late! AMRX Media Mentions By Week AMRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AMRX News Sentiment▼1.260.71▲Average Medical News Sentiment AMRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AMRX Articles This Week▼34▲AMRX Articles Average Week Get Amneal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ITCI News Today ROIV News Today ASND News Today RVMD News Today LEGN News Today NUVL News Today ELAN News Today LNTH News Today BPMC News Today CYTK News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AMRX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amneal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amneal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
